Findings

What do systematic reviews say?

7 questions · 7 findings · 2 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 28.6%Low 0 · 0%Moderate 3 · 42.9%High 2 · 28.6%

All‐cause mortality · adults in sinus rhythm after cardioversion of atrial fibrillation

Sotalol leads to higher all‐cause mortality compared with placebo or no treatment (high certainty).

1 finding from 1 review

Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation 2019 · Cochrane Headline outcomes only
RR 2.23 [1.03, 4.81]
5 studies · 1882 participants
High

Withdrawals due to adverse events · adults in sinus rhythm after cardioversion of atrial fibrillation

Sotalol probably leads to higher withdrawals due to adverse effects compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation 2019 · Cochrane Headline outcomes only
RR 1.95 [1.23, 3.11]
12 studies · 2688 participants
Moderate

Proarrhythmia · adults in sinus rhythm after cardioversion of atrial fibrillation

Sotalol probably leads to higher proarrhythmia compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation 2019 · Cochrane Headline outcomes only
RR 3.55 [2.16, 5.83]
12 studies · 2989 participants
Moderate

Stroke · adults in sinus rhythm after cardioversion of atrial fibrillation

Sotalol showed no clear difference in stroke compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation 2019 · Cochrane Headline outcomes only
RR 1.47 [0.48, 4.51]
3 studies · 1161 participants
Moderate

Recurrence of atrial fibrillation · adults in sinus rhythm after cardioversion of atrial fibrillation

Sotalol leads to lower recurrence of atrial fibrillation compared with placebo or no treatment (high certainty).

1 finding from 1 review

Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation 2019 · Cochrane Headline outcomes only
RR 0.83 [0.8, 0.87]
14 studies · 3179 participants
High

Sudden cardiac death · participants with high risk of sudden cardiac death (secondary prevention)

It is very uncertain whether amiodarone changes sudden cardiac death compared with sotalol (very low certainty).

1 finding from 1 review

Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death 2015 · Cochrane Headline outcomes only
RR 2.87 [0.32, 25.55]
1 study · 45 participants
Very low

All‐cause mortality · participants with high risk of sudden cardiac death (secondary prevention)

It is very uncertain whether amiodarone changes all‐cause mortality compared with sotalol (very low certainty).

1 finding from 1 review

Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death 2015 · Cochrane Headline outcomes only
RR 1.08 [0.41, 2.83]
2 studies · 104 participants
Very low